Completed PHASE2 INTERVENTIONAL 2-arm NCT01485848

EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer (ESP2011-002)

EP-100, a Novel LHRH Receptor-Targeted, Membrane-Disrupting Peptide, Plus Paclitaxel Versus Paclitaxel Alone for Refractory or Recurrent Ovarian Cancer: A Phase II, Randomized, Multicenter Trial

Sponsor: Esperance Pharmaceuticals Inc

Conditions Ovarian Cancer Recurrent

Interventions EP-100 Paclitaxel

Updated 6 times since 2017 Last updated: Jun 9, 2014 Started: Feb 29, 2012 Primary completion: May 31, 2014 Completion: May 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01485848, this PHASE2 trial focuses on Ovarian Cancer Recurrent and remains completed. Sponsored by Esperance Pharmaceuticals Inc, it has been updated 6 times since 2012, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Feb 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Esperance Pharmaceuticals Inc

Data source: Esperance Pharmaceuticals Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bozeman, United States , Covington, United States , Greenbrae, United States , Houston, United States , Kennewick, United States , Louisville, United States , Middletown, United States , Mount Vernon, United States , Portland, United States , San Francisco, United States and 4 more locations